Source link : https://www.newshealth.biz/health-news/for-treatment-value-imatinib-remains-the-cml-gold-standard/
When it comes to selecting a cost-effective, first-line tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia (CML), consider the treatment goal. For survival, generic imatinib remains the gold standard, Elias Jabbour, MD, said during a session at the annual meeting of the Society of Hematologic Oncology in Houston. For treatment-free remission, generic […]
Author : News Health
Publish date : 2024-09-06 05:05:40
Copyright for syndicated content belongs to the linked Source.
Categories